“I think BCI is going to be massive. It could be one of the largest areas in all of Medtech.” - Tom Oxley, CEO of Synchron During our LSI USA ‘24 Fireside Chat, Kimberly Ha was joined by Thomas Oxley and Andy Rasdal who shared insights on Synchron’s approach, the challenges they've faced, and highlighted the real-world impact of BCIs. Synchron is a neurotechnology company developing an endovascular BCI designed to restore functionality in patients with severe paralysis. Currently in human clinical trials, their first product is a BCI that enables people with impaired upper limb function to control digital devices directly from the brain. Tune into the full Fireside Chat to hear more about the true potential of BCI and the approach Synchron is taking to restore independence and functionality to individuals with severe paralysis. “Neurotechnology to Address the Limitations of the Human Body” is available on our website and YouTube channel: https://lnkd.in/gin8USRx
It was awesome to meet Thomas Oxley in person at LSI. Scott Pantel and Henry Peck thanks for finding some great speakers!
Totally agree that BCI is going to be massive. the WHO estimates that ~50 million people worldwide are affected by neurodegenerative disorders and it is expected to rise. Being at the forefront of understanding how the brain works and finding novel ways to reroute neural signals to bring back function is such a game changer. This would drastically improve QoL for millions around the world.